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Abstract  
This study explores the regulation and importance of System L amino acid transport in a 
murine model of T cell acute lymphoblastic leukemia (T-ALL) caused by deletion of 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN). There has been a 
strong focus on glucose transport in leukemias but the present data show that primary T-ALL 
cells have increased transport of multiple nutrients. Specifically, increased leucine transport 
in T-ALL fuels mammalian target of rapamycin complex 1 (mTORC1) activity which then 
sustains expression of hypoxia inducible factor-1α (HIF1α) and c-Myc; drivers of glucose 
metabolism in T cells. A key finding is that PTEN deletion and phosphatidylinositol (3,4,5)-
trisphosphate (PtdIns(3,4,5)P3) accumulation is insufficient to initiate leucine uptake, 
mTORC1 activity, HIF1α or c-Myc expression in T cells and hence cannot drive T-ALL 
metabolic reprogramming. Instead, a key regulator for leucine transport in T-ALL is 
identified as NOTCH. Mass spectrometry based proteomics identifies SLC7A5 as the 
predominant amino acid transporter in primary PTEN
-/-
 T-ALL cells. Importantly, expression 
of SLC7A5 is critical for the malignant transformation induced by PTEN deletion. These data 
reveal the importance of regulated amino acid transport for T cell malignancies, highlighting 
how a single amino acid transporter can play a key role. 
©    2017 Macmillan Publishers Limited. All rights reserved.
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Introduction 
The proliferation of normal and malignant T lymphocytes is supported by signaling pathways 
that increase nutrient uptake to meet cellular metabolic demands. Immune activated normal T 
cells and malignant T cells thus increase glucose uptake and switch to glycolysis to use 
glucose as a carbon source for their increased biosynthetic demands (1-7). In normal T cells, 
glucose metabolism is controlled by c-Myc and HIF1 transcription factors which regulate 
expression of genes encoding glucose transporters and glycolytic enzymes (4,8). The 
serine/threonine kinase mTORC1 also selectively coordinates glucose transport and 
glycolysis by controlling the expression of HIF1α (4,9). One important question is whether 
the metabolic reprogramming of transformed T cells replicates the metabolic reprograming of 
normal proliferating T cells? In this respect, T-ALL are aggressive tumors of T cell 
progenitors caused by mutations in NOTCH pathway (10) or mutations/loss of expression of 
PTEN, a lipid phosphatase with specificity for the 3′ position of PtdIns(3,4,5)P3 (11,12). T-
ALL have high glucose metabolism (5-7) and c-Myc (13-15), mTORC1 (16-18) and HIF1α 
(19,20) are important for their development. However, in contrast to normal T cells, it is not 
known if there is an mTORC1/HIF regulatory circuit in T-ALL.  
One mechanism that coordinates c-Myc and mTORC1 signaling in normal T cells is the 
control of amino acid uptake (21). mTORC1 activity requires sustained leucine and 
glutamine transport (22). Moreover, c-Myc protein has a very short half-life and can only 
accumulate in T cells exhibiting high levels of amino acid uptake and protein synthesis (23). 
The regulated supply of large neutral amino acids (LNAA) mediated by the System L amino 
acid transporter SLC7A5 (also known as LAT1) is particularly important in T cells for 
mTORC1 activity and c-Myc expression (21). What about amino acid transport in malignant 
T cells? Human and mouse malignant T cells express CD98 (SLC3A2) (24,25), one subunit 
of the System L amino acid transporter complex. T-ALL also express Slc7a5 mRNA and 
©    2017 Macmillan Publishers Limited. All rights reserved.
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there is evidence that pharmacological blockade of System L transport suppresses leukemia 
growth (26). However there has been no direct analysis of the amino acid transport capacity 
in primary T-ALL. Accordingly, the present study explores amino acid transport in a mouse 
model of T cell leukemia/lymphoma where thymic deletion of the inositol phosphatase PTEN 
drives rapid T leukemogenesis/lymphomagenesis (25,27,28). We show that PTEN-null 
malignant T cells have high membrane transport capacity for multiple nutrients including 
high System L amino acid transporter activity driven by NOTCH signaling pathways. 
Moreover, amino acid supply via System L amino acid transporters underpins metabolic 
reprogramming controlled by mTORC1, c-Myc and HIF1α in malignant T cells and is critical 
for the in vivo malignant transformation induced by PTEN deletion. 
  
©    2017 Macmillan Publishers Limited. All rights reserved.
 5 
Methods 
 
Mice 
Mice were maintained in the University of Dundee in compliance with UK Home Office 
Animals (Scientific Procedures) Act 1986. C57BL/6 Pten
fl/fl
Lck-Cre, Hif1a
fl/fl
Lck-Cre, 
Pten
fl/fl
Hif1a
fl/fl
Lck-Cre and Pten
fl/fl
Slc7a5
fl/fl
Lck-Cre mice were bred and genotyped as 
described in supplemental methods. Experiments were performed using mice between 4 and 
6 weeks of age when studying non-transformed PTEN
-/-
 T cells, to ensure the absence of 
transformed T cells.  
 
Cell cultures and Flow cytometry  
F014 and F15 murine PTEN
-/-
 T-ALL cells (29), primary murine cytotoxic T cells (30), OP9-
DL-1 and control OP9 bone marrow stromal cells (31) were maintained as described 
previously. Standard flow cytometric protocols were used to monitor surface antigens and 
intracellular S6 phosphorylated on Ser235 and Ser236 (32). Details of antibodies used are in 
supplemental methods. Data were acquired on LSR Fortessa or FACSVerse machines 
(Becton Dickinson) and analyzed using FlowJo software (TreeStar). 
 
Nutrient uptakes 
Glucose, glutamine and leucine transport were measured using [
3
H]-2-deoxyglucose (1 μCi 
ml
−1
), [
3
H]-L-glutamine/[
14
C]-L-glutamine or [
3
H]-L-leucine as described previously (21). 
APC-transferrin uptakes were performed as described previously (23). 
 
Protein detection and mRNA quantitation 
Immunoblotting for protein expression and phosphorylation and label free quantitative mass 
spectrometry protocols for protein quantification were as described in (9) and detailed 
protocols and details of antibodies used are in supplemental methods. Details of mRNA 
purification and protocols for quantitation by PCR are in supplemental methods.  
 
Statistical analyses 
Data sets were analyzed using SigmaPlot 12.5 (Systat) or Prism 6.0 (GraphPad). A Shapiro-
Wilk test for normality was performed to determine suitable tests for parametric or non-
parametric populations. F-tests were performed to determine equal variance of populations, 
otherwise tests assuming unequal variance were performed. All utilized tests were two-tailed 
©    2017 Macmillan Publishers Limited. All rights reserved.
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and are stated in the respective figure legends. Multiple comparisons in one-way ANOVA 
analyses were corrected for using the Holm-Sidak method. Kaplan-Meier survival analyses 
were performed for the Pten
fl/fl
Lck-Cre, Pten
fl/fl
Hif1αfl/flLck-Cre and Ptenfl/flSlc7a5fl/flLck-Cre 
tumor model.  
  
©    2017 Macmillan Publishers Limited. All rights reserved.
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Results 
Increased transport of leucine and multiple nutrients in primary PTEN
-/-
 T-ALL cells 
Mice with PTEN alleles floxed by loxP Cre excision sequences were backcrossed to Lck-Cre 
transgenic mice that express Cre recombinase selectively in thymic T cell progenitors. 
Pten
fl/fl
Lck-Cre
+ 
mice serve as a murine model of T-ALL as mice develop aggressive T cell 
lymphomas in the thymus that are fatal at approximately 8-12 weeks (25,28). Primary ex vivo 
PTEN
-/-
 T-ALL cells can be isolated from Pten
fl/fl
Lck-Cre
+ 
mice for analysis of nutrient 
transport. Figure 1a shows high rates of glucose and glutamine uptake, respectively, in 
primary ex vivo T-ALL cells isolated from Pten
fl/fl
Lck-Cre
+
 mice compared to the nutrient 
uptake of wild-type thymocytes. Primary PTEN
-/-
 T-ALLs also expressed CD71, the 
transferrin receptor and had high rates of transferrin uptake compared to wild-type 
thymocytes (Fig.1b). Moreover, PTEN
-/- 
T-ALL cells expressed high levels of CD98, a 
subunit of System L amino acid transporters. They also had increased uptake of the large 
neutral amino acid (LNAA) leucine compared to wild-type thymocytes. This was comparable 
to leucine transport levels of CTL (cytotoxic T cells) (Fig.1c) used as a positive control due 
to their high rates of amino acid transport (3,4,21,23). Two murine PTEN
-/-
 T-ALL cell lines 
derived from Pten
fl/fl
Lck-Cre
+
 mice, F04 and F15 (29), also showed constitutively high 
transport of multiple nutrients including glucose, glutamine, transferrin and leucine as well as 
high expression of CD71 and CD98 (Suppl.Fig.1).  
 
Nutrient transport in T-ALL is not directly driven by PtdIns(3,4,5)P3 or AKT  
In many cells, signaling pathways mediated by PtdIns(3,4,5)P3 and the serine/threonine 
kinase AKT control nutrient transport (33). However, in normal effector T cells the 
regulation of nutrient uptake is phosphatidyl-3 kinase (PI3K)/AKT independent (3,4). The 
Pten
fl/fl
Lck-Cre
+
 mouse model allows the isolation of PTEN
-/-
 non-transformed thymocytes 
©    2017 Macmillan Publishers Limited. All rights reserved.
 8 
from young (4-6 week old) mice (34). These PTEN
-/-
 non-transformed thymocytes have been 
well characterized (25,34) and are known to be polyclonal and lack the secondary mutations 
associated with T-ALL. They had high levels of active AKT and increased phosphorylation 
of the AKT substrate PRAS40 T246 (Fig.2a). The analysis of nutrient uptake in PTEN
-/-
 non-
transformed thymocytes allows an assessment of the ability of PtdIns(3,4,5)P3 and AKT to 
drive nutrient transport in T cells. The data show that PTEN
-/-
 non-transformed thymocytes 
did not increase glucose or glutamine transport (Fig.2b) nor did they express CD71 or 
increase transferrin uptake (Fig.2c). PTEN-/- non-transformed thymocytes also had very low 
CD98 expression and leucine transport (Fig.2d). The failure to see increased nutrient 
transport in PTEN
-/-
 non-transformed thymocytes shows that AKT activation is insufficient 
for these processes. Thus, the changes in nutrient transport in PTEN
-/- 
T-ALL must be a 
consequence of the secondary mutations that drive malignant transformation in these cells 
(35,36).  
 
Expression of c-Myc, HIF1α and mTORC1 activity in PTEN-/- T-ALL 
Increases in glucose, glutamine and transferrin uptake in immune activated normal T cells are 
regulated by c-Myc and mTORC1, the latter via control of expression of HIF1 complexes 
(4,8,23). High levels of c-Myc expression are characteristic of T-ALL either as a result of c-
Myc translocations or NOTCH signaling (14,15,37,38). Hence, wild-type and PTEN
-/- 
non-
transformed
 
thymocytes had no detectable expression of c-Myc (Fig.3a) and NOTCH1 
(Suppl.Fig.2a), whereas c-Myc protein was readily observed in primary PTEN
-/- 
T-ALL cells 
(Fig.3a). What about mTORC1 activity and HIF1α expression in primary PTEN-/- T-ALL 
cells? Initially we probed mTORC1 activity by analyzing the phosphorylation of p70S6 
kinase 1 (S6K). Figure 3b shows high levels of S6K phosphorylation on T389, the mTORC1 
substrate site, in primary ex vivo isolated PTEN
-/- 
T-ALL cells. This S6K T389 
©    2017 Macmillan Publishers Limited. All rights reserved.
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phosphorylation was lost when cells were treated with the mTORC1 inhibitor, rapamycin. 
We also assessed mTORC1 activity in PTEN
-/- 
T-ALL cells by quantifying levels of enzymes 
that control lipid biosynthesis. Their expression is known to be controlled via mTORC1 
regulation of the activity of sterol regulatory element binding proteins (SREBPs) (39). This 
analysis revealed upregulation of SREBP regulated signaling pathways in PTEN
-/- 
T-ALL 
cells compared with wild-type thymocytes (Fig.3c). We then analyzed the expression of 
HIF1α and found that ex vivo isolated PTEN-/- T-ALL cells expressed HIF1α which was in 
stark contrast to wild-type thymocytes where no HIF1α was detected (Fig.3d, Suppl.Fig.2b). 
Hypoxia promotes the accumulation of HIF1α (40): levels of HIF1α in ex vivo PTEN-/- T-
ALL PTEN
-/- 
T-ALL cells declined in normoxia (21% O2) but were increased by hypoxia 
(1% O2) (Fig.3d). In contrast, ex
 
vivo isolated wild-type and PTEN
-/-
 non-transformed 
thymocytes did not have high mTORC1 activity (Fig.3b), nor did they express detectable 
HIF1α or increase HIF1α expression under in hypoxia (Suppl.Fig.2b,c) although they did 
express HIF1β (Suppl.Fig.2d).  
To address if HIF1α expression in T-ALL cells is controlled by mTORC1 we switched to 
experiments with PTEN
-/-
 T-ALL cell lines (29). Figure 3e shows that the murine PTEN
-/-
 T-
ALL cell lines, F04 and F15, had high levels of mTORC1 activity as judged by the 
rapamycin sensitive phosphorylation of S6K T389 and expressed HIF1α under hypoxia and 
normoxia (Fig. 3f). Inhibition of mTORC1 with rapamycin, resulted in a strong decrease in 
HIF1α expression (Fig.3g). Inhibition of mTORC1 in the T-ALL cells also caused a decrease 
in expression of c-Myc (Fig.3h). Furthermore, mTORC1 activity was also required to sustain 
glucose uptake in PTEN
-/-
 T-ALL cells (Fig. 3i). 
How important is the ability of mTORC1 to control HIF1α expression in PTEN-/- T-ALL 
cells? In this context, selective deletion of mTORC1 activity in T cell progenitors extends 
mouse lifespan in models leukaemogenesis induced by PTEN deletion (18); although cells 
©    2017 Macmillan Publishers Limited. All rights reserved.
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that have genetically disrupted mTORC1 signaling eventually develop T cell tumors. Hif1αfl/fl 
Lck-Cre
+
 mice had normal numbers and frequencies of thymocyte subsets, indicating that 
deletion of HIF1α in T cell progenitors in the thymus does not impair normal T cell 
development (Fig.3j). Pten
fl/fl
Lck-Cre
+ 
mice had a median survival of 68 days and only a 
small percentage of these mice (14%) survived beyond 100 days. In contrast, Pten
fl/flHif1αfl/fl 
Lck-Cre
+
 mice showed prolonged survival with a median life span of 127 days, although they 
eventually developed PTEN
-/-
 x HIF1α-/- T cell tumors (Fig.3k) that had high rates of glucose 
transport (Fig.3l, Suppl.Fig.3). HIF1α is thus important although not essential for T 
lymphomagenesis caused by PTEN deletion and HIF1α independent signaling pathways can 
control glucose transport in T-ALL.  
  
T-ALL and System L amino acid transport  
One striking observation was the low levels of mTORC1 activity in PTEN
-/-
 non-transformed 
thymocytes compared to the high mTORC1 activity in malignant PTEN
-/- 
T-ALL cells 
(Fig.3b). PtdIns(3,4,5)P3 accumulation and AKT activation (Fig.2a) were thus insufficient 
for mTORC1 activition in thymocytes. One key requirement for mTORC1 activity in PTEN
-/- 
T-ALL cells was the sustained transport of leucine (Fig.4a) consistent with the leucine 
requirement for mTORC1 activity in other cell systems (21,41). Hence, the low mTORC1 
activity in PTEN
-/-
 non-transformed thymocytes (Fig.3b) was consistent with the absence of 
leucine transport in these cells (Fig.2d).  
What are the leucine transporters in PTEN
-/- 
T-ALL cells? Leucine is preferentially 
transported by System L amino acid transporters which are heterodimers consisting of CD98 
and either SLC7A5 (LAT1), SLC7A8 (LAT2); SLC7A7 (y
+
LAT1) or SLC7A6 (y
+
LAT2) 
(42). Mass spectrometry proteomic analysis of primary ex vivo PTEN
-/- 
T-ALL cells from 3 
tumor bearing Pten
fl/fl
 Lck-Cre
+ 
mice identified that these cells expressed CD98, SLC7A5 and 
©    2017 Macmillan Publishers Limited. All rights reserved.
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SLC7A6, with SLC7A5 always more abundant than SLC7A6 (Fig.4b). SLC7A5 has a key 
role in peripheral T cells, controlling mTORC1 activity and c-Myc expression (21), known 
drivers of T-ALL (13,43). In contrast deletion of Slc7a5 in T cell progenitors in the thymus 
does not impair normal T cell development (21). However, SLC7A5 loss dramatically 
impairs the development of T cell malignancy: Pten
fl/fl
Slc7a5
fl/fl
 Lck-Cre
+
 mice thus showed 
prolonged survival (358 days median surivival) compared to the rapid morbidity of 
Pten
fl/fl
Lck-Cre
+ 
mice (68 day median survival) (Fig.4c). Out of 18 Pten
fl/fl
Slc7a5
fl/fl
 Lck-Cre
+ 
mice, only 6 mice developed very late onset PTEN
-/- 
x SLC7A5
-/-
 T cell tumors 
(Suppl.Fig.4). SLC7A5 is therefore a dominant System L amino acid transporter in this T-
ALL model.  
 
NOTCH1 regulation of leucine uptake in T-ALL  
How do T-ALL control SLC7A5  expression and LNAA transport? We have shown that 
changes in leucine transport in PTEN
-/-
 T-ALL cells were not a direct consequence of PTEN 
deletion or AKT activation as they were not seen in PTEN
-/-
 non-transformed thymocytes 
(Fig.2b-d). We then considered other possible drivers for the changes in leucine transport in 
T-ALL, and focused on NOTCH. The rationale was that NOTCH activation occurs 
frequently in human and murine T-ALL (10) and is known to control mTORC1 activity and 
expression of c-Myc (15,44) and can also drive glucose and glutamine uptake (45).  
Initial experiments addressed the role of NOTCH in regulating leucine transport directly in 
wild-type thymocytes. We used the OP9-DL1 system where OP9 cells expressing the 
NOTCH ligand delta-like 1 (DL1) support the differentiation and self-renewal of T cell 
progenitors (46). Figure 5a shows that thymocytes maintained in IL-7 on OP9 cells had low 
levels of leucine transport in contrast to the high levels of leucine uptake in NOTCH-
stimulated cells. This leucine uptake was mediated by System L amino acid transporters as 
©    2017 Macmillan Publishers Limited. All rights reserved.
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evidenced by its sensitivity to the System L competitor BCH (Fig.5a). Leucine uptake was 
mirrored by the expression of CD98, a subunit of System L amino acid transporter (Fig.5b). 
Furthermore, only thymocytes that increased leucine uptake showed active mTORC1, as 
determined by phosphorylation of the S6K substrate, S6 on S235/236 (Fig.5c).  
What about the role of NOTCH in established PTEN
-/-
 T-ALL? The T-ALL cell lines F04 
and F15 have constitutive NOTCH activity as there is high expression of the NOTCH1 
intracellular domain (IC NOTCH1) which is released by NOTCH1 gamma-secretase 
cleavage between G1743 and V1744 (Fig.5d). The gamma-secretase inhibitor, DAPT, 
blocked the accumulation of the IC NOTCH1 (V1744) and caused loss of NOTCH 
transcriptional activity as judged by the loss of expression of c-Myc (Fig.5d). F04 and F15 
cells also had high rates of leucine transport that could be partially blocked by NOTCH1 
inhibition (Fig.5e). DAPT treated F04 and F15 cells also lost mTORC1 activity, HIF1α 
expression and glucose transport capacity (Fig.5d and 5f, respectively). NOTCH inhibition 
in F04 and F15 cells also decreased expression of Slc7a5 (Fig.5g) and Cd98 (Fig.5h). 
NOTCH signals thus sustain expression of System L amino acid transporters and LNAA 
transport in PTEN
-/-
 T-ALL cells. 
  
©    2017 Macmillan Publishers Limited. All rights reserved.
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Discussion 
The importance of understanding metabolic checkpoints in malignant cells is now clear. 
Much work in leukemias has focused on important changes in glucose metabolism but other 
nutrients such as amino acids and iron are equally important (26,47). The present data 
highlight how primary PTEN
-/-
 T-ALL cells switch to high rates of transport of multiple 
nutrients and one discovery is that primary ex vivo T-ALL have high System L amono acid 
transport capacity. Moreover, the regulated transport of LNAA via the amino acid transporter 
SLC7A5 is key for T cell malignancy. Amino acid transport via System L transporters is 
important for protein synthesis but also supplies leucine which is essential to sustain 
mTORC1 activity in T-ALL cells. mTORC1 is able to control T-ALL metabolism by 
controlling expression of two key transcription factors c-Myc and HIF1α. The importance of 
c-Myc for T cell leukemia is well established (13). The present data show that HIF1α is also 
expressed in primary T-ALL cells and is critical for T-ALL development induced by PTEN 
deletion. In this respect, the impact of HIF1α deletion on the development of the T cell 
tumors following thymic deletion of PTEN phenocopies the impact of losing mTORC1 
activity (18). One role for HIF1α is to regulate the transcription of genes encoding glucose 
transporters and glycolytic enzymes. It was noteworthy that when Pten
fl/flHif1αfl/fl Lck-Cre+ 
mice did eventually develop tumors, they had high rates of glucose transport. Therefore, 
HIF1α independent signaling pathways can mediate glucose metabolism in T-ALL. One 
alternative regulator is c-Myc which controls the transcription of genes encoding glucose 
transporters and enzymes controlling glycolysis and glutaminolysis in T cells (8). Another 
key role for c-Myc is to control glucose flux through the hexosamine biosynthetic pathway 
which is also essential for the T lymphoma/leukemias driven by PTEN deletion (45). The 
importance of c-Myc and mTORC1 controlled pathways for malignant T cells would be one 
reason that an amino acid transporter such as SLC7A5 would also be important. c-Myc 
©    2017 Macmillan Publishers Limited. All rights reserved.
 14 
expression and mTORC1 activity in T cells are thus highly dependent on the regulated supply 
of amino acids via System L amino acid transporters (21,23). mTORC1 and c-Myc hence act 
as signaling hubs that connect amino acid transport to multiple metabolic processes. 
Loss and inactivation of PTEN and elevated PtdIns(3,4,5)3 and AKT activity is a common 
feature of T-ALL malignancy (12). In many cells PtdIns(3,4,5)P3/AKT signaling has a role to 
control the activity of mTORC1 (48). However, we show that PTEN loss and AKT activation 
alone is not sufficient to activate mTORC1 in T cells. The molecular basis for the inability of 
PTEN deletion alone to drive mTORC1 activity is that PTEN deletion alone is not sufficient 
to induce the transport of nutrients such as glucose, glutamine and leucine that are essential 
for mTORC1 activity. In the context of System L transporter expression, leucine transport 
and mTORC1 activity in T-ALL cells the present studies identify NOTCH as a key driver. 
The engagement of T cells with NOTCH ligands is thus sufficient to induce leucine transport 
in T cells. Moreover the loss of NOTCH signaling in established T-ALL cells results in loss 
of leucine transporters and a failure to sustain mTORC1 activity. Previous studies have 
shown the importance of NOTCH control of c-Myc (14,15). The NOTCH control of amino 
acid transport shown herein reveals a mechanism that allows NOTCH to co-ordinate the c-
Myc and also mTORC1 controlled metabolic pathways that are essential for T cell tumors 
(summary Fig.5i). These data reinforce previous ideas that pharmacological blockade of 
System L transport would be a valuable strategy to supress leukemia growth (26).  
 
©    2017 Macmillan Publishers Limited. All rights reserved.
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Figure legends 
Figure 1. PTEN
-/-
 T-ALL cells upregulate nutrient transport 
Thymocytes isolated from Pten
fl/fl
Lck-Cre
-
 or tumour bearing Pten
fl/fl
Lck-Cre
+
 (T-ALL) mice 
were assayed for (a) 
3
H-2-deoxyglucose and 
3
H-glutamine uptake, (b) CD71 expression and 
APC-transferrin uptake, and (c) CD98 expression and 
3
H-leucine uptake; 
3
H-leucine uptake 
in cytotoxic T cells (CTL) is shown as a positive control. The glucose analogue 2-
deoxyglucose was used to indicate glucose uptake. Representative nutrient uptake data shown 
include technical triplicate values, error bars indicate standard deviation. The data shown are 
representative of 3 biological replicates. 
 
Figure 2. PTEN
-/-
 non-transformed thymocytes have active AKT but do not upregulate 
nutrient uptake  
Thymocytes were isolated from Pten
fl/fl
Lck-Cre
-
, Pten
fl/fl
Lck-Cre
+
 and tumour-bearing 
Pten
fl/fl
Lck-Cre
+
 (T-ALL) mice. (a) Immunoblots for phospho-AKT (T308) and (S473), 
phospho-PRAS40 (T246) and total AKT, PRAS40 and SMC1. Where indicated, cells were 
treated with Akti inhibitor (1μM, 1h), or pervanadate (100 μM, 10 min) to drive maximum 
AKT activity. (b) 
3
H-2-deoxyglucose and 
3
H-glutamine uptake from thymocytes of indicated 
genotypes. (c) Flow cytometry data of CD71 expression and APC-transferrin uptake. (d) 
CD98 expression and 
3
H-leucine uptake from thymocytes of indicated genotypes. When 
indicated CTL were used as a positive control. The data shown are representative of (a,c) 3; 
(b,d) 4 biological replicates for each genotype.  
 
Figure 3. Active mTORC1 controls HIF1α expression that is important for 
tumorigenesis in PTEN
-/-
 TALL 
©    2017 Macmillan Publishers Limited. All rights reserved.
 21 
(a-d) Thymocytes were isolated from Pten
fl/fl
Lck-Cre
-
, Pten
fl/fl
Lck-Cre
+
 and tumor-bearing 
Pten
fl/fl
Lck-Cre
+
 (T-ALL) mice. Immunoblots show (a) c-Myc and SMC1 expression, (b) 
phospho-S6K (T389), S6K and SMC1 expression. Thymocytes were treated as indicated with 
rapamycin (20nM, 1h), or phorbol ester (25ng/ml, 1h) as a positive control; (c) Whole 
proteome mass-spectrometry analysis of thymocytes isolated from 3 tumor bearing 
Pten
fl/fl
Lck-Cre
+
 (T-ALL) mice compared with thymocytes from 3 wild-type Pten
fl/fl
Lck-Cre
-
 
mice. Shown is the fold change of estimated copy numbers of SREBP2 targets. (d) 
Immunoblot for HIF1α and SMC1 expression from thymocytes lysed directly after isolation 
(ex vivo) or cultured under 21% (normoxia) or 1% (hypoxia) of O2 for 4h (left panel). Right 
panel: Densitometry analysis (ImageJ) of HIF1α expression in ex vivo isolated cells relative 
to loading control, each point is a biological replicate, n=4 for Pten
fl/fl
Lck-Cre
-
 and n=5 for 
Pten
fl/fl
Lck-Cre
+
, **P < 0.01 (t-test). (e-h) Immunoblot data from T-ALL cell lines F04 and 
F15 show (e) expression of phospho-S6K (T389), total S6K and SMC1 from cells treated 
rapamycin (20nM, 1h) or untreated; (f) shows expression of HIF1α, HIF1β, AKT and SMC1 
from cells cultured in 21% (normoxia) or 1% (hypoxia) O2 for 4h and (g) expression of 
HIF1α, phospho-S6K (T389), phospho-AKT (T308) and SMC1 and (h) c-MYC and SMC1  
from cells +/- rapamycin (20nM) for indicated times. (i) 
3
H-2-deoxyglucose uptake of F04 
and F15 cells treated with or without rapamycin (20nM, 48h). (j) Thymocyte numbers from 
Hif1a
wt/wt
Lck-Cre
+
 and Hif1a
fl/fl
Lck-Cre
+
 mice, each point shown is a biological replicate, 
n=5. Total thymic cell number (left panel);  thymocyte progenitor populations (right panel). 
NS-not significant (t-test). (k) Kaplan-Meier survival plot comparing kinetics of tumor 
development in Pten
fl/fl
Lck-Cre
+
 (n=34) mice with Pten
fl/fl
Hif1a
fl/fl
Lck-Cre
+ 
(n=41) mice. P-
value was calculated by Log rank (Mantel-Cox) test. (l) 
3
H-2-deoxyglucose uptake from ex 
vivo isolated Pten
fl/fl
Hif1a
fl/fl
Lck-Cre
-
 and Pten
fl/fl
Hif1a
fl/fl
Lck-Cre
+ 
T-ALL cells. The data 
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shown are representative of (a,b) 5 and (k) 3 biological replicates for each genotype. The 
data shown in (e-i) are representative of 4 independent experiments.  
 
Figure 4. Leucine transporter SLC7A5 is crucial for mTORC1 activity and 
tumorigenesis in PTEN
-/-
 T-ALL cells 
(a) Flow cytometry of phospho-S6 (S235/236) expression in murine F04 T-ALL cells 
maintained in complete RPMI +/- rapamycin (20nM) or RPMI lacking leucine or HBSS (no 
amino acids) for indicated times. The data are representative of 3 independent experiments. 
(b) Histograms showing the distribution of estimated copy numbers of individual proteins as 
measured by whole proteome mass-spectrometry from thymocytes isolated from 3 tumor 
bearing Pten
fl/fl
Lck-Cre
+
 (T-ALL) mice. The estimated protein copy number of CD98, 
SLC7A6 and SLC7A5 are indicated. Protein copy number is quantified with   the proteome 
ruler and presented as log- transformed mean values. (c) Kaplan-Meier survival plot 
comparing kinetics of tumor development in Pten
fl/fl
Lck-Cre
+
 (n=18) mice compared with 
Pten
fl/fl
Slc7a5
fl/fl
Lck-Cre
+ 
(n=18) mice. P-value was calculated by Log rank (Mantel-Cox) 
test.  
 
Figure 5. NOTCH signals are essential for maintenance of leucine transport in PTEN
-/-
 
T-ALL cells 
(a-c) DN thymocytes isolated from wild-type mice were cultured on OP9 or OP9-DL1 in the 
presence of IL-7 (5 ng/ml, 48h) (a) 
3
H-leucine uptake +/- System L transport inhibitor BCH 
(10mM), (b) CD98 expression and (c) intracellular phospho-S6 (S235/236) expression. (d-h) 
Murine T-ALL cell lines F04 and F15 were treated +/- DAPT (10μM) or rapamycin (20nM) 
for 48h; (d) immunoblot data showing expression of intracellular NOTCH1 (V1744), c-Myc, 
phospho-S6K (T389), HIF1α, phospho-AKT (T308), AKT and SMC1, (e) 3H-leucine uptake 
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+/- BCH (10mM), (f) 
3
H-2-deoxyglucose uptake. (g) Relative mRNA expression of Slc7a5 
and (h) relative mRNA expression of Cd98. mRNA levels were normalized to Cd45, *P < 
0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA). (i) Schematic diagram of changes 
observed in non-transformed thymocytes from Pten
fl/fl
Lck-Cre
+
 and T-ALL cells from tumor 
berung Pten
fl/fl
Lck-Cre
+ 
mice. PTEN
-/-
 non-transformed thymocytes have low levels of 
mTORC1 activity and do not express c-Myc, HIF1α or NOTCH1. They also have low levels 
of nutrient transport. Malignant transformation leads to formation of PTEN
-/-
 TALL that have 
high levels of mTORC1 activity and express HIF1α, NOTCH1 and c-Myc. They also have 
increased nutrient transport. Active NOTCH1 drives expression of System L transporters and 
as a consequence leucine transport. Leucine uptake leads to an increase in mTORC1 activity. 
Active mTORC1 controls expression of HIF1α and glucose uptake in PTEN-/- TALL. 
Additionally, NOTCH1 controls expression of c-Myc, a potential alternative driver for 
glucose transport (8). c-Myc expression is also regulated by mTORC1. Expression of c-Myc 
can be important for increased transport of glutamine (8) and iron (23) in PTEN
-/-
 TALL. The 
data shown are mean from 2 biological replicates, error bars standard deviation and 
representative of (b,c) 3 biological replicates, , (d) 4 independent experiments. (e,f) Each 
point depicts an independent experimental replicate (n=3) consisting of the mean of technical 
triplicates. (g,h) Each point depicts an independent experimental replicate, n=5. 
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